The alliance offers customers access to early formulation and analytical method development, aseptic and non-aseptic manufacturing of liquids, powders, gels, and lyophilized drug products, as well as labelling, kitting, storage and shipment services.
Al Hansen, chairman and chief executive officer of Bioserv, said, “This opportunity to ally with Advantar is unique and mutually beneficial as our capabilities align well with theirs. Our collaboration creates multiple synergies that will benefit customers in terms of quality, timeliness and cost-effectiveness.”
Richard Kenley, Ph.D., president and chief executive officer of Advantar, said, “Advantar has teamed successfully with Bioserv in the past, and we are excited about establishing a more formal basis for our alliance. We expect to jointly provide customers with unrivalled offerings in drug product development and manufacturing, and to reliably advance customers’ programs from early development through the approval and launch phases.”